Camostat mesylate, a protease inhibitor, has been found to cause significant increase in the bicarbonate concentration, secretory rate, and output of pancreatic juice of dogs. Furthermore it was found that this water induction and bicarbonate secretion increase was achieved via direct regulation of ductular cells of the dog pancreas. Other studies have shown Camostat mesylate to suppress spinal Fos expression in the rat, which is a marker for neuronal activation. In addition it was shown that this compound may prevent or depress pancreatitis-induced referred allodynia/hyperalgesia in rat models. Camostat mesylate has also demonstrated the ability to prevent Trypsin attack of microspheres, which causes the degradation product N-benzoyl-dl-arginine. Camostat mesylate is an inhibitor of KLK, plasminogen, Prothrombin and Trypsin.
1. Horiuchi, A., et al. 1990. J. Pharmacol. Exp. Ther. 252: 320-326. PMID: 1688943
2. Uchida, T., et al. 2001. J. Pharm. Pharmacol. 53: 255-261. PMID: 11273024
3. Ishikura, H., et al. 2007. Life Sci. 80: 1999-2004. PMID: 17433371
4. Togami, K., et al. 2009. Rinsho Ketsueki. 50: 1700-1705. PMID: 20068277
See how others have used Camostat mesylate (CAS 59721-29-8). Click on the entry to view the PubMed entry .
PMID: # 26485396 Nimishakavi, S.|Raymond, WW.|Gruenert, DC.|Caughey, GH.| et al. 2015. PLoS ONE. 10: e0141169.
PMID: # 24963801 Butterworth, MB.|Zhang, L.|Liu, X.|Shanks, RM.|Thibodeau, PH.| et al. 2014. PLoS One. 9: e100313.
PMID: # 31550238 J. Clin. Invest.
PMID: # 22406536 J. Clin. Invest. 122: 1519-28.